Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
Date:10/2/2008

DETROIT, Oct. 2 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today that members of the Local 3, Service Employees International Union, CTW, have ratified a new labor agreement covering approximately 400 production and packaging employees at all of Caraco's facilities. The new four year agreement will be effective through September 21, 2012. It replaces the agreement originally set to expire September 12, 2008.

"We are pleased that the members of the Local 3, Service Employees International Union, CTW, have ratified this agreement as our employees are extremely important to Caraco's strategy and continued growth," said Daniel H. Movens, Caraco's Chief Executive Officer.

This press release should be read in conjunction with our Form 8-K, which provides more detailed information on the labor agreement.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
4. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
5. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
6. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
7. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in China, ... owner and founder. As Oat is recognized globally as one of the healthiest cereals, ... he believes it is a move to sow the seed of good karma. Buddhism ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern ... has recently joined their multi-specialty medical group. The dermatology practice provides general ... , “We’re excited to add this excellent dermatology practice to our group’s medical ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel ... Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety of ...
(Date:1/20/2017)... ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has ... the world. Yisrayl says this generation is a time like no other and society needs ... Bible. , Yisrayl says he does not want to sound like an old bible beater ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted ... had a successful January ECRM Trade Show in Hilton Head, SC. , Bionic ... it to provide its products to all clients at reasonable prices. At the ECRM ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , VAE, January 20, 2017 ... stark gestiegenen Bedarf an Nothilfe   Die internationale ... Platz für Hilfsgüter zu schaffen   ... und Premierminister der VAE sowie Herrscher von ... der internationalen Stadt der Hilfe (International Humanitarian City IHC) ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
Breaking Medicine Technology: